NCT05904340 Transcutaneous Electrical Acupoint Stimulation on Symptoms Associated with Chemotherapy Induced Peripheral Neuropathy
| NCT ID | NCT05904340 |
| Status | Recruiting |
| Phase | — |
| Sponsor | National Taipei University of Nursing and Health Sciences |
| Condition | Breast Neoplasms |
| Study Type | INTERVENTIONAL |
| Enrollment | 86 participants |
| Start Date | 2023-07-01 |
| Primary Completion | 2025-04-30 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 86 participants in total. It began in 2023-07-01 with a primary completion date of 2025-04-30.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Breast cancer ranks first in Taiwan's top ten gynecological cancers. Chemotherapy is a standard treatment method for colorectal cancer and breast cancer, but while destroying cancer cells, it also destroys healthy cells, resulting in side effects. Peripheral neuropathy can lead to peripheral nerve damage and decreased activity, which affects the patient's quality of life. Currently, there is no standard and effective method for treating peripheral neuropathy caused by chemotherapy. Therefore, the purpose of this study is to investigate the effect of percutaneous electrical acupoint stimulation on improving peripheral nerve symptoms in breast cancer patients undergoing chemotherapy.
Eligibility Criteria
Inclusion Criteria: 1. Primary diagnosed with breast cancer for the first time by a physician. 2. Patients who have completed chemotherapy or postoperative adjuvant chemotherapy within 3 months, and the chemotherapy drugs used are paclitaxel, vinblastine or platinum drugs. 3. Patients who have been evaluated by doctors as peripheral neuropathy caused by chemotherapy, and whose symptoms persist after completing chemotherapy. 4. Peripheral sensory or peripheral motor neuropathy grade ≥ 2 in general toxicity criteria (NCI-CTCAE). 5. Those who have clear consciousness and can communicate in Mandarin or Taiwanese. Exclusion Criteria: 1. Patients suffering from carcinoma in situ. 2. Patients suffering from stage IV cancer. 3. Patients suffering from metastatic cancer. 4. Patients receiving peripheral neuropathy drugs (Duloxetine) 5. Patients receiving acupoint stimulation therapy. 6. Patients who are allergic to silicone patches. 7. Patients with cardiac pacemakers. 8. Patients suffering from diabetic peripheral neuropathy. 9. Patients suffering from peripheral neuropathy of acquired immunodeficiency syndrome. 10. Patients receiving treatment for mental illness.
Contact & Investigator
WANG, PHD
PRINCIPAL INVESTIGATOR
National Taipei University of Nursing and Health Sciences
Frequently Asked Questions
Who can join the NCT05904340 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 80 Years, studying Breast Neoplasms. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT05904340 currently recruiting?
Yes, NCT05904340 is actively recruiting participants. Contact the research team at henry1993110101@gmail.com for enrollment information.
Where is the NCT05904340 trial being conducted?
This trial is being conducted at Changhua, Taiwan.
Who is sponsoring the NCT05904340 clinical trial?
NCT05904340 is sponsored by National Taipei University of Nursing and Health Sciences. The principal investigator is WANG, PHD at National Taipei University of Nursing and Health Sciences. The trial plans to enroll 86 participants.